This review highlights #OncolyticViruses as emerging #tumor therapeutics and summarizes advances in combining OVs with #immunotherapy—from #CheckpointInhibitors to cellular therapies—showing promise for improved outcomes.

#OpenAccess: doi.org/10.1016/j.ge...

#Immunology #CancerImmunotherapy #Tcells #CheckpointInhibitors

Thank you to Dr. Hussein Tawbi @mdanderson.bsky.social
for presenting our #GrandRounds, sharing the latest advancements in immune #checkpointinhibitors for #melanoma that has metastasized to the brain.
Watch his full talk: youtube.com/watch?v=cGWS...

Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis - Linjing Zhou, Yuwei Li, Le Wang, Kaiyan Chen, Shichao Zhou, Yunfei Chen, Jing Sun, Yunfeng Tong, Yun Fan, 2025 Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy, with or without angiogenesis inhibitors, have been investigated as the first-line tr...

Adding anti-angiogenesis therapy to PD-1/PD-L1 + chemo improves PFS and ORR in ES-SCLC, especially in patients under 65. No OS benefit overall. Safety comparable.
🔗 buff.ly/tMshYDZ
#LungCancer #CheckpointInhibitors #MetaAnalysis

Relationship between HBsAg/HBV DNA and prognosis in patients with HBV-related hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors - Qiuying Qin, Yuanyuan Zheng, Yiran Wang, Fei Zhou, Dong Li, Linlin Jin, Mujia Zhu, Yabing Guo, Rong Fan, Jinlin Hou, Xiaoyong Zhang, Hongyan Liu, 2025 Objectives: Blocking the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis could reverse the immune tolerance in the liver microenviron...

PD-1/PD-L1 inhibitors show promise in HBV-related hepatocellular carcinoma. Patients with low HBV DNA and early qHBsAg response had longer survival. Viral biomarkers could shape future immunotherapy strategies. buff.ly/ciwROOE
#LiverCancer #HBV #CheckpointInhibitors

📎 feeds.issuerdirect.com/news-release...

💡Research-use pembrolizumab from MedChemExpress: medchemexpress.com/Lambrolizuma...

#ESMO2025 #ESMO25 #mRNA #Inhibitors #CancerTherapy #ImmunoOncology #CheckpointInhibitors

Turning All Cancers Into Curable Diseases - Dr. Karen Knudsen MBA PhD - CEO, Parker Institute for Cancer Immunotherapy, joins me on Progress, Potential, And Possibilities #ProstateCancer #CARTCellTherapy #CheckpointInhibitors #TumorAntigens #TumorMicroenvironment www.youtube.com/watch?v=cyrO...

Advances in Vaccines, Checkpoint Blockade, and Chimeric Antigen Receptor−Based Cancer Immunotherapeutics

www.dl.begellhouse.com/journals/2ff...

#CancerImmunotherapy #CheckpointInhibitors #CARTTherapy

Treatment of NSCLC after chemoimmunotherapy — are we making headway? - Nature Reviews Clinical Oncology Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage driver-negative non-small-cell lung cancer (NSCLC), although most patients will ultimately have dis...

💡 Take-home message: Restoring antitumor immunity via multimodal, biomarker-guided strategies is the next frontier in post-ICI NSCLC.

#LungCancer #NSCLC #ImmunoOncology #CheckpointInhibitors #Medicalwatch
www.nature.com/articles/s41...

Immunotherapy for Cancer Success Rate: What Patients Need to Know in 2025 - OncoDaily Discover the immunotherapy for cancer success rate across tumor types, based on clinical trials and real-world data. A patient guide to outcomes and expectations.

Immunotherapy for Cancer Success Rate: What Patients Need to Know in 2025

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #Immunotherapy #SuccessRate #CART #CheckpointInhibitors #ICIs

Scancell points to 'strong' melanoma vaccine data Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.

#Scancell #NationalCancerInstitute #UKbiotech #DNAplasmidvaccine #melanoma #SCOPEtrial #SCIB1 #iSCIB1+ #checkpointinhibitortherapy #advancedmelanoma #immunotherapy #melanomaantigens #TRP2protein #Tcells #checkpointinhibitors #metastaticmelanomatreatment
pharmaphorum.com/news/scancel...

Discovering mechanisms of response via CSI (Cancer Systems Immunology) mathematical-oncology.org

In this week's post Jesse Kreger (@adamlmaclean.bsky.social‬) discusses his latest work in #cancer #systems #immunology together with Edgar Gonzalez to study the mechanisms of response of breast cancer to #checkPointInhibitors

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.

Nivolumab + relatlimab show promising intracranial activity in melanoma brain metastases! A beacon of hope for resistant cases and a call for more research!
#Melanoma #BrainMetastases #Immunotherapy #Nivolumab #Relatlimab #CheckpointInhibitors #TCSC #Oncology

www.cancernetwork.com/view/nivolum...

Immune Treatment May Work Against Several Cancer Types - Baby Kids Health New research shows immune treatment may work against several cancer types, offering hope beyond surgery and chemo.

A New Hope in the Fight Against Cancer 🧬✨

www.babykidshealth.com/immune-treat...

#cancertreatment #immunotherapy #healthnews #hopeforcancer #checkpointinhibitors #immunehealth #cancerresearch #dostarlimab #cancerhope #cancersurvivor #healthrevolution #fightcancer #sciencewins #health #healthnews

🎥 New on #OncologyBytes from #IUCS2024
Dr. Anupama Vijay shares a real-world UK audit of 1L mRCC treatment.
📊 Only 64% of patients received 2L therapy after progression.
📺 Watch: youtu.be/Qix6-H83_nw
🌐 Learn more at: oncoassist.com

#mRCC #RenalCancer #CheckpointInhibitors #Oncoassist #UKOncology

🎥 New on #OncologyBytes from #IUCS2024

Dr. Yüksel Ürün validates the MEET-URO prognostic score in real-world mRCC patients treated with Ipi/Nivo, Cabo/Ipi/Nivo & Pembro/Axi.
📺 Watch: youtu.be/k2BA8sVHD-Y

🌐 Learn more at: oncoassist.com

#mRCC #RenalCancer #PrognosticScore #CheckpointInhibitors

TIL is a form of #immunotherapy but is different from #checkpointinhibitors or #CARTcell therapy. Dr. Lee leads the TIL Therapy Program at Fred Hutch, which is the only cancer center in Washington, Idaho, Montana and Alaska that offers FDA-approved TIL therapy for melanoma. 3/10

Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies Li et al. analyze CD8+ T cells collected from HNSCC patients treated with neoadjuvant immunotherapies. They show that different combination immunotherapies modulate CD8+ T cell functional states throu...

💡 Takeaway: Different ICI combinations drive distinct CD8+ T cell dynamics, shaping immune responses for better outcomes! 💪🦠

#Immunotherapy #CancerResearch #CheckpointInhibitors #TCellBiology #Oncology #HeadAndNeckCancer

www.cell.com/cancer-cell/...

SCI members Nam Bui, Kristen Ganjoo & colleagues found that several #sarcoma types showed the highest RR and longest PFS. Their work offers insights into 54 sarcoma histologic and immunologic factors linked to response to immune #CheckPointInhibitors. pubmed.ncbi.nlm.nih.gov/39699310/

Kidney cancer at ESMO 2024: CONTACT-03, TiNivo-2 and SUNNIFORECAST - VJOncology Ignacio Duran, MD, PhD, Hospital Universitario Marques de Valdecilla, Santander, Spain, comments on recent kidney cancer research presented at the...

#KidneyCancerAwarenessWeek 🌍 🗞️

Dr. Ignacio Duran, Hospital Universitario Marques de Valdecilla, shares insights from key #kidneycancer studies presented at the ESMO 2024 Congress💡🎥

👉 https://buff.ly/42gQE9Y

#ESMO2024 #KidneyCancerResearch #OncologyUpdates #CheckpointInhibitors

Pembrolizumab-induced Thyroiditis, Hypophysitis and Adrenalitis: A Case of Triple Endocrine Dysfunction Abstract. Immune checkpoint inhibitor drugs can trigger autoimmune endocrine reactions as a known side effect. Several cases of immunotherapy-induced autoi

#Pembrolizumab -induced #thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction. doi.org/10.1210/jcem...
Featured in #JCEMCaseReports #OpenAccess
#adrenal #pituitary #CheckpointInhibitors
@endocrinesociety.bsky.social

#CureCancer #AdvancedTherapies #Biopharma #PrecisionMedicine #CheckpointInhibitors #TCellTherapy #SolidTumorTherapy #HematologicCancers #StemCellResearch #CancerTreatment #TumorTargeting #TranslationalResearch #BiotechRevolution #ImmunoOncology #FutureOfMedicine #BreakthroughScience

#CureCancer #AdvancedTherapies #Biopharma #PrecisionMedicine #CheckpointInhibitors #TCellTherapy #SolidTumorTherapy #HematologicCancers #StemCellResearch #CancerTreatment #TumorTargeting #TranslationalResearch #BiotechRevolution #ImmunoOncology #FutureOfMedicine #BreakthroughScience

📝 Conclusion
It is crucial to ensure ICIs’ benefits in cancer care aren’t offset by renal complications. Timely diagnosis, avoiding ATIN-associated drugs, and leveraging patient-specific data on biomarkers is key
#Nephrology #Immunotherapy #CheckpointInhibitors

#checkpointinhibitors #PD1 #CTLA4 #NKcells #PersonalizedMedicine #PrecisionMedicine #ImmunoOncology #CancerTherapy #mRNATherapy #RegenerativeMedicine #Crispr #Bcell

#immunotherapy #cancerimmunotherapy #celltherapy #CARtherapy #CAR_T #CAR_T_cell #stemcells #iPSCs #geneediting #oncology #cancerresearch #biotech #BiotechTwitter #Immunology #ClinicalTrials #CancerVaccine #TCRtherapy #Tcell #checkpointinhibitors